Retatrutide is a next-generation triple-agonist metabolic therapy currently in clinical development for weight management and metabolic health support. Designed to activate GIP, GLP-1, and glucagon receptors, retatrutide represents a new class of multi-pathway incretin therapies engineered to deliver powerful effects on appetite control, energy balance, and metabolic function.
No products were found matching your selection.